

JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com CIN NO. L74899DL1978PLC009181

May 30, 2023

The Department of Corporate Services-Listing	The Department of Corporate Services- Listing
BSE Ltd,	National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers,	Exchange Plaza, C-1, Block G,
Dalal Street	Bandra Kurla Complex,
Mumbai-400 001	Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

Subject: Annual Secretarial Compliance Report for the financial year ended March 31, 2023 under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the Financial Year ended March 31, 2023.

We request you to take the above on record.

Thanking you,

For Jagsonpal Pharmaceuticals Limited

Abhishek Joshi Company Secretary & Compliance Officer

Encl.: A/a

Secretarial Compliance Report

Of Jagsonpal Pharmaceuticals Limited for the year ended 2022-23

We have examined:

- (a) all the documents and records made available to us and explanation provided by Jagsonpal Pharmaceuticals Limited ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 2022-23 in respect of compliance with the provisions of :

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued there under; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made there under and the Regulations, circulars, guidelines issued there under by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued there under, have been examined, including:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; not applicable on relevant Financial year 2022-23
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; not applicable on relevant Financial year 2022-23
- (e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

The Nomination and Remuneration committee has approved the grant of 14,67,920 (Fourteen Lakh sixty seven thousand nine hundred and twenty shares) employee stock option under Jagson Pal Pharmaceuticals Limited Employee Stock Option Plan, 2022.

(f) Securities and Exchange Board of India (Issue and Listing of Debt, Securities) Regulations, 2008; not applicable on relevant Financial year 2022-23 Company

Chamber No. 304, 12/1117, Naiwala, Karol Bagh, New Delhi-110005 Ph.: 28754547, (M)9810015715

Secretaries M.No. 4819

- (g) Securities and Exchange Board of India(Issue and Listing of Non- Convertible and Redeemable Preference Shares) Regulations,2013; not applicable on relevant Financial year 2022-23
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) Securities and Exchange Board of India (Delisting of Equity Shares) (Amendment) Regulations, 2016; not applicable on relevant Financial year 2022-23
- (j) Securities and Exchange Board of India (Investor Protection and Education Fund) Regulations, 2009;
- (k) Securities and Exchange Board of India (Depository Participant) Regulations, 2018; and circulars/ guidelines issued there under;

We hereby report that, during the Review Period the compliance status of the listed entity is appended below;

Sr. No.	Particulars	Compliance status (Yes/ No/ NA)	Observations/ Remarks PCS*
1	Secretarial Standards:The compliances of the listed entity are in accordance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries of India (ICSI)	YES	None
2	 Adoption and timely updation of the Policies: All applicable policies under SEBI Regulations are adopted with the approval of board of directors of the listed entities All the policies are in conformity with SEBI Regulations and has been reviewed & timely updated as per the regulations / circulars/guidelines issued by SEBI 	YES	None
3	Maintenance and disclosures on Website: The Listed entity is maintaining a functional website	YES	None

	 Timely dissemination of the documents/ information under a separate section on the website Web-links provided in annual corporate governance reports under Regulation 27(2) are accurate and specific which re-directs to the 	YES	None		
	relevant document(s)/ section of the website				
4	Disgualification of Director:				
	None of the Director of the Company are disqualified under Section 164 of Companies Act, 2013	YES	None		
5	To examine details related to Subsidiaries of listed entities:				
	(a) Identification of material subsidiary companies	NA	None		
	(b) Requirements with respect to disclosure of material as well as other subsidiaries	NA	None		
6	Preservation of Documents:				
	The listed entity is preserving and maintaining records as prescribed under SEBI Regulations and disposal of records as Documents per Policy of Preservation of and Archival policy prescribed under SEBI LODR Regulations, 2015.	YES None			
7	Performance Evaluation:				
	The listed entity has conducted performance evaluation of the Board, Independent Directors and the Committees at the start of every financial year as prescribed in SEBI Regulations	YES	None		
8	Related Party Transactions:				
	 (a) The listed entity has obtained prior approval of Audit Committee for all Related party transactions 	YES	None		

	(b) In case no prior approval obtained, the listed entity shall provide detailed reasons along with confirmation whether the transactions were subsequently approved/ ratified/ rejected by the Audit committee	YES	None
9	Disclosure of events or information: The listed entity has provided all the required disclosure(s) under Regulation 30 along with Schedule III of SEBI LODR Regulations, 2015 within the time limits prescribed thereunder.	YES	None
10	Prohibition of Insider Trading:		- 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940 - 1940
	The listed entity is in compliance with Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015	YES	None
11	Actions taken by SEBI or Stock Exchange(s), if any: No Actions taken against the listed entity/ its promoters/ directors/ subsidiaries either by SEBI or by Stock Exchanges(including under the Standard Operating Procedures issued by SEBI through various circulars) under SEBI Regulations and circulars/ guidelines issued there under.	NO	NSE and BSE have imposed a penalty of Rs 10,000 each for the violation of Regulation 29(2)/ 29(3) and the same was paid by the company on 27/9/2022.
12	Additional Non-compliances, if any: No any additional non-compliance observed for all SEBI regulation/ circular/guidance note etc.	YES	None



*Observations/Remarks by PCS are mandatory if the Compliance status is provided as 'No' or 'NA'

• The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below: -

Sr. no	Compliance Requirement (Regulations/ circulars / Guidelines including specific clause)	Regul ation/ Circu lar No.	De vi ati on s	Actio n Take n by	Typ e of viola tion	Details of violation	Fine Amo unt	Observatio ns/ Remarks of the Practicing Company Secretary	Manage ment Response	Remark
1	Non- compliance of Regulation 29(2)/ 29(3) of SEBI (LODR) Regulation, 2015	Regul ation 29(2)/ 29(3)	-	NSE	Fine/ Pena lty	Non- complian ce of Regulati on 29(2)/ 29(3) of SEBI (LODR) Regulati on, 2015	Rs. 10000 (exclu ding taxes)	The company has complied with said regulation and no further action is required to be taken by the company	The company has complied with the said regulation by payment of requisite fine/ penalty	Paid on 27 th Septemb er, 2022.
2	Non- compliance of Regulation 29(2)/ 29(3) of SEBI (LODR) Regulation, 2015	Regul ation 29(2)/ 29(3)		BSE	Fine/ Pena lty	Non- complian ce of Regulati on 29(2)/ 29(3) of SEBI (LODR) Regulati on, 2015	Rs. 10000 (exclu ding taxes)	The company has complied with said regulation and no further action is required to be taken by the company	The company has complied with the said regulation by payment of requisite fine/ penalty	Paid on 27 th Septemb er, 2022.



 The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. no	Compliance Requirement (Regulations/ circulars / Guidelines including specific clause)	Regul ation/ Circu lar No.	Dev iati ons	Action Taken by	Type of viola tion	Detai ls of viola tion	Fine Amount	Observ ations/ Remark s of the Practici ng Compa ny Secreta ry	Manage ment Response	Remark
-	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

For Mukesh Arora & Co. Company Secretaries

> Company Constants M.No. 4819

(MUKESH ARORA) Prop. FCS No. 4819 CP No. 4405 UDIN NO:F004819E000354245

Place: New Delhi Date: 23-05-2023